What is the expected market price of Lynparza in 2025?

Olaparib As the first PARP inhibitor approved for marketing , it is a new type of targeted drug targeting the DNA damage repair mechanism. Since its development and launch by AstraZeneca, olaparib has quickly occupied a place in the treatment of various solid tumors such as breast cancer, ovarian cancer, prostate cancer and pancreatic cancer. As it is officially approved in China and included in medical insurance, the price system and drug purchase channels have become key issues of concern to many patients.

Currently in mainland China, the original drug Lynparza has been launched and has been included in the National Medical Insurance Category B Category B for use in patients who meet specific indications. Common dosage forms include100mg tablets (56 tablets) and 150mg tablets (56 tablets). The price of a single box is about RMB 6,000. However, under the medical insurance reimbursement policy, patients who meet the indications can receive substantial cost compensation, and the patient out-of-pocket ratio has dropped significantly, greatly reducing the originally high burden of targeted therapy.

In comparison, the overseas pricing of Lynparza is significantly higher. For example, in the United States, a box of 150 mg of original medicine can cost around US$8,000 (approximately RMB 60,000), which also highlights the importance of domestic medical insurance policies in terms of drug accessibility. Against this background, some patients have also begun to look for more cost-effective alternatives through overseas purchasing.

Currently, there are multiple versions of olaparib generics on the market in countries such as Laos and Bangladesh. For example, the generic version of olaparib produced by Beacon Pharmaceutical Company in Bangladesh is basically the same as the original drug in terms of drug ingredients and specifications. Taking the specification of 50 mg × 112 tablets as an example, each box sells for about more than 2,000 yuan, which is suitable for patients who are price-sensitive but have medical needs. However, when choosing such generic drugs, patients should ensure that they obtain them through formal channels and avoid purchasing non-certified products.

Reference materials:https://www.lynparza.com/